Trade names Deltyba Protein binding ≥99.5% | ATC code J04AK06 (WHO) Molar mass 534.48 g/mol | |
 | ||
AHFS/Drugs.com International Drug Names Routes ofadministration by mouth (film-coated tablets) Legal status In general: ℞ (Prescription only) | ||
Hope in the pipeline new drugs bedaquiline sirturo delamanid deltyba
Delamanid, sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
Contents
- Hope in the pipeline new drugs bedaquiline sirturo delamanid deltyba
- Medical uses
- Adverse effects
- Interactions
- History
- Society and culture
- References
Common side effects include headache, dizziness, and nausea. Other side effects include QT prolongation. It has not been studied in pregnancy as of 2016. Delamanid works by blocking the manufacture of mycolic acids thus destabilising the bacteria's cell wall.
Delamanid was approved for medical use in 2014 in Europe, Japan, and South Korea. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2016 the Stop TB Partnership had an agreement to get the medication for 1,700 USD per six month for use in more than 100 countries.
Medical uses
Delamanid is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis.
Adverse effects
Common side effects include headache, dizziness, and nausea. Other side effects include QT prolongation. It has not been studied in pregnancy as of 2016.
Delamanid prolongs the QT interval.
Interactions
Delamanid is metabolised by the liver enzyme CYP3A4, wherefore strong inducers of this enzyme can reduce its effectiveness.
History
In phase II clinical trials, the drug was used in combination with standard treatments, such as four or five of the drugs ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. Healing rates (measured as sputum culture conversion) were significantly better in patients who additionally took delamanid.
The European Medicines Agency (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness.
Society and culture
The medication was not readily available globally as of 2015. It was believed that pricing will be similar to bedaquiline, which for six months is approximately 900 USD in low income countries, 3,000 USD in middle income countries, and 30,000 USD in high income countries. As of 2016 the Stop TB Partnership had an agreement to get the medication for 1,700 USD per six month.